Leads Pharmacology Side effects 
European Pharmaceutical Review
JANUARY 11, 2024
The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies.
Pharmaceutical Technology
NOVEMBER 17, 2022
This delay in diagnosis ultimately leads to disease progression and associated complications, such as chronic pelvic pain and infertility, which greatly affects the patients’ quality of life. However, NICE stated it will further explore new approaches to address these unmet needs during scoping of the update.
Legacy MEDSearch
JUNE 15, 2023
The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Impetus Digital
AUGUST 2, 2024
In theory, this will allow for highly tailored, personalized therapy plans with superior efficacy and minimal side effects. In turn, this can support decision-making and lead to more efficient inventory management and faster delivery times, enhance supply chain visibility and transparency, and avoid overproduction and waste.
European Pharmaceutical Review
JULY 18, 2024
1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of side effects. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Pharmaceutical Representative Training
JUNE 22, 2024
Technological advancements, shifting market dynamics, and updated regulations are leading to significant changes within the pharmaceutical industry. Preventing Misuse: Strict regulations are required to stop the improper use and abuse of drugs, especially those that have strong side effects or the potential to become addictive.
Expert insights. Personalized for you.
102 
Let's personalize your content